A natural selection. (biotechnology pioneer Genentech Inc.) (Cover Story): An article from: Chief Executive (U.S.)

This digital document is an article from Chief Executive (U.S.), published by Chief Executive Publishing on May 1, 1992. The length of the article is 2955 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

From the supplier: Biotechnology pioneer Genentech Inc has demonstrated a stability and innovativeness that has made it a leader in the industry for the past 16 years. Genentech's past success is expected to continue in the future as a result of its 1990 decision to sell 60% of the company to Roche Holding's US division for $2.1 billion. The deal brings several benefits to Genentech. For one, it eases the multimillion burden of funding the marketing of its genetically engineered products, wherein product promotions can continue for at least seven years. The link-up with Roche also marks the entry of Genentech into the international market and provides Genentech with access to Roche's global marketing network. The step-up of marketing efforts for Genentech's chief anti-clotting product, Activase, and the introduction of three new products will be greatly enforced by the Roche deal.

Citation Details
Title: A natural selection. (biotechnology pioneer Genentech Inc.) (Cover Story)
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: May 1, 1992
Publisher: Chief Executive Publishing
Issue: n76 Page: p34(4)

Article Type: Cover Story

Distributed by Thomson Gale